SCHEMBL1143797

SCHEMBL1143797

CCOc1cc(C(CC(=O)N2CCOCC2)N2Cc3cccc(NC(C)=O)c3C2=O)ccc1OC(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.46
PDE4B Q07343 6/20 0.46
PDE4C Q08493 6/20 0.46
PDE4D Q08499 6/20 0.46
HTR2B P41595 1/20 0.43
TP53 P04637 1/20 0.40
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
STAT3 P40763 1/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
NR1I2 O75469 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1143574 0.88 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL1143654 0.87 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL1143494 0.87 PDE4B (0.60) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL1143447 0.87 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL1143358 0.87 PDE4B (0.49) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL1144136 0.86 PDE4B (0.64) PDE4APDE4BPDE4CPDE4DHTR2B
Cyclopropane SCHEMBL4200950 0.80 PDE4B (0.51) PDE4APDE4BPDE4CPDE4DHTR2B
Cyclopropane SCHEMBL4206831 0.79 TP53 (0.46) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL1143639 0.79 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DHTR2B
SCHEMBL5496470 0.79 NR1I2 (0.42) PDE4APDE4BPDE4CPDE4DHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587474-B1 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2009-11-18 EP claimed
US-20070072902-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses TRIMERIS, INC. 2007-03-29 US claimed
US-7173058-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2007-02-06 US claimed
EP-1587474-A4 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2006-11-22 EP claimed
EP-1587474-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-10-26 EP claimed
EP-1587474-A3 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-09-15 EP claimed
US-20040204448-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-10-14 US claimed
WO-2004060313-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-07-22 WO claimed
US-8158672-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2012-04-17 US disclosed
US-8158672-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2012-04-17 US disclosed
US-8158672-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2012-04-17 US disclosed
US-20110124645-A1 FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION 2011-05-26 US disclosed
US-20110124645-A1 FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION 2011-05-26 US disclosed
US-20110124645-A1 FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION 2011-05-26 US disclosed
EP-1587474-A4 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2006-11-22 EP disclosed
EP-1587474-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-10-26 EP disclosed
EP-1587474-A3 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-09-15 EP disclosed
US-20040204448-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-10-14 US disclosed
WO-2004060313-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-07-22 WO disclosed
WO-2004060313-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124645-A1 FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES PDE4A, PDE4B, PDE4D PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885
US-20070072902-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses PDE4A, PDE4B, PDE4D PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885
US-20040204448-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses PDE4A, PDE4B, PDE4D PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.